home / stock / cslly / cslly news


CSLLY News and Press, CSL Ltd. ADR From 12/07/25

Stock Information

Company Name: CSL Ltd. ADR
Stock Symbol: CSLLY
Market: OTC

Menu

CSLLY CSLLY Quote CSLLY Short CSLLY News CSLLY Articles CSLLY Message Board
Get CSLLY Alerts

News, Short Squeeze, Breakout and More Instantly...

CSLLY - Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years PR Newswire - 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through fiv...

CSLLY - Washington state resident dies from bird flu strain never before detected in humans

2025-11-22 08:33:19 ET More on GSK, Sanofi, etc. GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript CSL Limited (CSLLY) Analyst/Investor Day Prepared Remarks Transcript GSK plc (GSK) Q3 2025 Earnings Call Transcript AnaptysBio dr...

CSLLY - Australian biotech CSL announces $1.5B investment in the U.S.

2025-11-18 10:59:06 ET More on CSL CSL Limited (CSLLY) Analyst/Investor Day Prepared Remarks Transcript CSL Limited (CSLLY) Shareholder/Analyst Call Transcript CSL Limited (CSLLY) Shareholder/Analyst Call - Slideshow Seeking Alpha’s Quant Rating on CSL...

CSLLY - CSL Limited (CSLLY) Analyst/Investor Day Prepared Remarks Transcript

2025-11-04 23:46:25 ET CSL Limited (CSLLY) Analyst/Investor Day November 4, 2025 6:00 PM EST Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Paul McKenzie - MD, CEO & Executive Director Dave Ross - Senior VP & GM of Se...

CSLLY - CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

2025-10-28 04:57:39 ET CSL Limited (CSLLY) Shareholder/Analyst Call October 27, 2025 7:01 PM EDT Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Brian McNamee Paul McKenzie - MD, CEO & Executive Director Brian Daniel...

CSLLY - CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) PR Newswire Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0 ™ principles with sustainable ...

CSLLY - Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines

Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines PR Newswire Real-world evidence (RWE) data estimate 19.8% relative vac...

CSLLY - My Top 5 Biotech Stocks Big Pharma Could Buy Next

2025-10-06 13:29:00 ET On September 17 , the Fed began cutting interest rates again, which historically preceded Big Pharma's increased activity in the M&A space.... Read the full article on Seeking Alpha For further details see: My Top 5 Biotech Stocks Big Pharm...

CSLLY - CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B

CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B Canada NewsWire OTTAWA, Ontario , Oct. 6, 2025 /CNW/ -- CSL Behring...

CSLLY - CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy Canada NewsWire FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland ...

Previous 10 Next 10